Comparing Gamma Knife radiosurgery and microsurgery for brain metastases
Dose-staged Gamma Knife Radiosurgery Versus Microsurgical Resection - Evaluation of Neurosurgical Treatment Methods for Patients With Larger Brain Metastases - an Explorative Prospective Study
NA · Medical University of Vienna · NCT04857905
This study is testing whether a non-invasive treatment called Gamma Knife radiosurgery works better than traditional surgery for people with certain types of brain tumors and limited brain metastases.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Medical University of Vienna (other) |
| Locations | 1 site (Vienna) |
| Trial ID | NCT04857905 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of dose-staged Gamma Knife radiosurgery compared to microsurgical resection in treating brain metastases. It focuses on patients with specific types of primary tumors and limited brain metastases, assessing outcomes based on tumor volume and patient health status. The study aims to provide a non-invasive treatment option for patients who may not be suitable for traditional surgery. Participants will be monitored for treatment efficacy and safety.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 90 with specific primary cancers and limited brain metastases who can tolerate both treatment options.
Not a fit: Patients with more than three brain metastases or those with contraindications for either treatment option may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a less invasive treatment option for patients with brain metastases, potentially improving their quality of life and outcomes.
How similar studies have performed: Previous studies have shown promising results for Gamma Knife radiosurgery in treating brain metastases, indicating that this approach has potential based on existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years and under 90 years * Patients with KPS ≥70 * Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor * Maximum of three brain metastases on the diagnostic MRI * Tumor volume of 8-20 ccm3 on the diagnostic MRI * Lobular brain metastases * Patients without any contraindications for both treatment options * Written, signed informed consent for study particaption after study explanation Exclusion Criteria: * Patients under 18 years and over 90 years * Patients with KPS \<70 * Patients with other primary tumor * More than three brain metastases on the diagnostic MRI * Tumor volume \<8 or \>20 ccm3 on the diagnostic MRI * Patients with contraindications for both treatment options
Where this trial is running
Vienna
- Department of Neurosurgery, Medical University of Vienna — Vienna, Austria (RECRUITING)
Study contacts
- Study coordinator: Josa Frischer, MD, PhD
- Email: josa.frischer@meduniwien.ac.at
- Phone: +43 1 40400 45510
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Brain Metastases, Gamma Knife Radiosurgery, Brain metastases, Microsurgical resection